The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Expansion In Market Value Is Forecasted For The Gene Therapy On Neurological Diseases Market Between 2026 And 2030?
The market for gene therapy on neurological diseases has expanded significantly in recent years. This market is forecasted to increase from $3.55 billion in 2025 to $4.01 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.0%. Historically, this expansion can be linked to several factors: limited gene therapy options for neurological diseases, the growing prevalence of alzheimer’s and parkinsons disease, a persistent reliance on conventional treatment methods, heightened awareness of genetic approaches, and initial clinical trials of viral vectors.
The gene therapy for neurological diseases market is poised for significant expansion in the coming years. It is projected to achieve a size of $6.48 billion by 2030, growing at a compound annual growth rate (CAGR) of 12.7%. The anticipated growth during this period can be attributed to several factors, including the advancement of adeno-associated virus and lentiviral therapies, the increased adoption of non-viral delivery platforms, a surge in regulatory approvals for neurological gene treatments, greater investment in research and development for precise genetic interventions, and the integration of digital monitoring and AI-assisted patient management. Prominent developments in the forecast period encompass escalating investment in both viral and non-viral gene therapy platforms, the broadening application of gene therapies across neurological disorders, an intensified focus on personalized and targeted genetic treatments, the proliferation of hospital and clinic-based gene therapy programs, and the innovation of advanced delivery methods for neurological gene therapy.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27294&type=smp
Which Key Factors Are Driving The Gene Therapy On Neurological Diseases Market Growth?
The increasing occurrence of neurological disorders is expected to drive the expansion of the gene therapy on neurological diseases market moving forward. Neurological disorders are health conditions that impact the brain, spinal cord, and nerves, leading to a variety of symptoms including cognitive, motor, and sensory impairments. The rising prevalence of neurological disorders is linked to the aging population, as aging gradually impairs neuronal function, reduces brain plasticity, and elevates oxidative stress, contributing to the development and progression of these conditions. Gene therapy for neurological diseases assists in managing these disorders by addressing their fundamental genetic causes, presenting potential long-term or permanent treatment solutions. It improves patient outcomes by restoring or modifying gene function, reducing symptoms, and minimizing the need for repetitive interventions, thereby enhancing overall quality of life. For instance, in July 2024, according to the National Health Service, a UK-based government agency, there were 487,432 patients diagnosed with dementia (a progressive brain disorder affecting memory, thinking, and daily activities) by June 30, 2024, an increase of 3,155 cases compared to May 31, 2024. Therefore, the growing incidence of neurological disorders is propelling the growth of the gene therapy on neurological diseases market.
Which Segment Classifications Are Used In The Gene Therapy On Neurological Diseases Market Segment Analysis?
The gene therapy on neurological diseases market covered in this report is segmented –
1) By Type: Viral Gene Therapy, Non-Viral Gene Therapy
2) By Target Disease: Alzheimer’s Disease, Parkinsons Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Multiple Sclerosis
3) By Administration Route: Intravenous, Intrathecal, Intranasal, Intracerebral, Other Administration Routes
4) By Application: Hospital, Clinic, Other Applications
Subsegments:
1) By Viral Gene Therapy Type: Adeno Associated Virus, Lentivirus, Retrovirus, Herpes Simplex Virus, Adenovirus
2) By Non-Viral Gene Therapy Type: Liposomes, Nanoparticles, Electroporation, Gene Gun, Naked Plasmid Deoxyribonucleic Acid (DNA)
What Trends Are Transforming The Gene Therapy On Neurological Diseases Market?
Firms operating within the gene therapy on neurological diseases market are concentrating on creating sophisticated viral delivery systems, specifically the adeno-associated virus serotype 2 (AAV2) vector, to enhance targeted gene delivery, boost effectiveness, minimize immune responses, and allow for prolonged therapeutic effects. The adeno-associated virus serotype 2 (AAV2) vector is defined as a modified, non-pathogenic viral carrier system employed in gene therapy to transport therapeutic genes into specific target cells, predominantly neurons, ensuring their sustained expression. As an illustration, in November 2024, PTC Therapeutics Inc., a biopharmaceutical firm based in the US, secured approval from the U.S. Food and Drug Administration (FDA) for its gene therapy designed to treat aromatic L-amino acid decarboxylase (AADC) deficiency. This particular therapy utilizes an AAV2 vector to introduce a functional DDC gene copy into the putamen, thereby facilitating dopamine production and enhancing motor functions. Characterized by a single, intraputaminal infusion, it aims to deliver lasting therapeutic advantages, considerably boosting motor function and alleviating debilitating symptoms without requiring subsequent treatments.
Which Firms Are Contributing To The Gene Therapy On Neurological Diseases Market Ecosystem?
Major companies operating in the gene therapy on neurological diseases market are Novartis AG, Biogen Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Oxford Biomedica plc, Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG
Get The Full Gene Therapy On Neurological Diseases Market Report:
Which Region Accounts For The Largest Portion Of The Gene Therapy On Neurological Diseases Market?
North America was the largest region in the gene therapy on neurological diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy on neurological diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Gene Therapy On Neurological Diseases Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Gene Therapy On Neurological Diseases Market 2026, By The Business Research Company
Switchboard Market Report 2026
https://www.thebusinessresearchcompany.com/report/switchboard-global-market-report
Mobile Computer Market 2026
https://www.thebusinessresearchcompany.com/report/mobile-computer-market
Surfing Boards Market Report 2026
https://www.thebusinessresearchcompany.com/report/surfing-boards-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model